- Home
- RGNX vs BHK Comparison
RGNX vs BHK Comparison
Compare RGNX & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGNX | BHK |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 654.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGNX | BHK |
|---|---|---|
| Price | $9.63 | $9.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 291.4K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | $8.86 |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $8.69 |
| 52 Week High | $16.19 | $10.12 |
Technical Indicators
Market Signals| Indicator | RGNX | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 52.00 |
| Support Level | $9.34 | $9.00 |
| Resistance Level | $9.67 | $9.21 |
| Average True Range (ATR) | 0.71 | 0.08 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 38.98 | 60.94 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.